An interventional study of Levagen+® Palmitoylethanolamide (PEA) and Placebo in Wellness, Psychological and Well-Being, Psychological, sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-13.
Sponsored by University of Westminster · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Psychological Well-Being with a site in United Kingdom — 34 open to participants now, 39 under way, none of them phase 3. Psychological Well-Being · United Kingdom.
Among the 105 studies in Psychological Well-Being with a site in United Kingdom, this one is the 44th largest by enrollment of the 78 interventional ones that give a count, is one of 10 that started in 2022, is one of 75 with no phase, and was the 67th registered.
2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.
Browse Psychological Well-Being studies →34 of the 105 studies in Psychological Well-Being with a site in United Kingdom are open now. Recruiting first, the newest first:
Lancashire and South Cumbria NHS Foundation Trust · Sites in United Kingdom
Ages 18+
London Metropolitan University · Sites in United Kingdom
Ages 18–100 · Healthy volunteers
Anna Freud · Sites in United Kingdom
Ages 10–17
Lucy Jonas · Sites in United Kingdom
Ages 16–18
Queen's University, Belfast · Sites in United Kingdom
Ages 18–68 · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2
First in 2007; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is below the median of 110 across 1,808 interventional studies indexed under Psychological Well-Being.
Median enrollment 82 across the 78 interventional studies, 120 across the 27 observational. Of the 51 that completed or were terminated, 7 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 105 have an industry lead sponsor. The 10 most frequent:
University of Westminster is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
University of Westminster has 1 study filed under Psychological Well-Being — fewer than ten, so there is no comparison to draw.
8 of the studies in Psychological Well-Being with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07399106Greater Manchester Mental Health NHS Foundation TrustEnhancing Child and Adolescent Mental Health Service Referrals 2 | 2026-11-30 |
| NCT07398365University of EdinburghMedical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients | 2026-12-31 |
| NCT06604104University of EdinburghVisual Frailty in Ageing | 2027-01-11 |
| NCT06425796University of UlsterAdiposity and Iron Requirements in Pregnancy | 2027-01-19 |
| NCT06937541University of West LondonFamily Interventions iN Dementia Mental Health Environments | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 105 studies in Psychological Well-Being with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomised cross-over trial is to learn about the effects of Levagen+® Palmitoylethanolamide (PEA) supplementation on cognition, wellness and well-being in young and healthy university students.
The main question it aims to answer is:
Participants will complete 2 baseline on-site visits during which they will be assigned to Levagen+® Palmitoylethanolamide (PEA) treatment or placebo arm each time and:
Researchers will compare the PEA treatment group to the placebo to see if there is a significant difference.
The study will investigate the effect of Levagen+® Palmitoylethanolamide (PEA) supplementation on parameters of stress, well-being and cognition at defined time points. Assessments will be made using a combination of a range of stress measures, which will include physiological and psychometric parameters.
Physiological measures will include assessments of known biomarkers of the principal stress-sensitive physiological systems, the hypothalamic-pituitary-adrenal axis, and the autonomic nervous system, while psychometric measures will include established instruments to assess general health, somatic stress symptoms, academic stress, response to stress, cognition, and mood.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levagen+® Palmitoylethanolamide (PEA) - 700mg/day, containing not less than 600 mg PEA.
Dietary Supplement: Levagen+® Palmitoylethanolamide (PEA)
Placebo - Microcrystalline Cellulose
Dietary Supplement: Placebo
Drug page: PalmidrolStudies of PalmidrolPalmidrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.
Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
To assess the influence of PEA supplementation on the perceived difficulties of test execution.
Motor Screening Task (MOT) was used as a screening tool to indicate difficulties in test execution as part of the Core Cognition battery - CANTAB by Cambridge Cognition.
Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on the reaction and movement speed and attention.
Reaction Time (RTI) was used to measure reaction and movement speed and attention as part of the Core Cognition battery - CANTAB by Cambridge Cognition.
Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on visual and episodic memory and visuospatial associative learning.
Paired Associated Learning (PAL) was used to measure visual and episodic memory and visuospatial associative learning as part of the Core Cognition battery - CANTAB by Cambridge Cognition.
Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on short-term and spatial working memory and problem solving.
Spatial Working Memory (SWM) was used to measure short-term and spatial working memory and problem solving as part of the Core Cognition battery - CANTAB by Cambridge Cognition.
Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on visual processing, recognition, and sustained attention.
Rapid Visual Information Processing (RVP) was used to assess visual processing, recognition, and sustained attention as part of the Core Cognition battery - CANTAB by Cambridge Cognition.
Time frame: The parameters were measured during the baseline visit (day 1) and during the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on Serum Brain-derived neurotrophic factor (BDNF) levels.
Serum BDNF levels were measured.
Time frame: The parameters were measured at the baseline visit (day 1) and at the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on HRV in female population.
HRV was measured for 3 full days.
Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.
To study the influence of PEA supplementation on the degree of perceived stress in females.
The Perceived Stress Scale (PSS) a 10-item questionnaire was used to measure the degree to which situations in the participant's life were appraised as stressful. The questions investigate how often certain feelings and thoughts were experienced on a five-point scale from 'never' to 'very often' (never =0, almost never = 1, sometimes = 2, fairly often = 3 and very often = 4) during the 3-day observation periods. To calculate a total PSS score, responses to the four positively stated items (items 4, 5, 7 and 8) first need to be reversed (i.e. 0 =\> 4; 1 =\> 3; 2 =\> 2; 3 =\> 1; 4 =\> 0). The PSS score were then obtained by summing across all items. Higher scores indicate higher levels of perceived stress.
Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.
To study the influence of PEA supplementation on perceived emotions in females.
The Positive and Negative Affect Schedule (PANAS) was used to assess feelings of both positive and negative emotions experienced simultaneously.
Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.
To study the influence of PEA supplementation on well-being in females.
Student Well-being Process Questionnaire (WPQ) a 44-item questionnaire was used to examine predictors of positive well-being, adverse mental health, and cognitive function. The responses to questions 1 - 42 were assessed on a 10-point scale and or questions 43 and 44 on a 4-point scale. Where with outcomes related to positive well-being high scores = more positive; with outcomes related to adverse mental health high scores = more negative and with outcomes related to cognitive function high scores = more cognitive problems. Positive well-being was predicted by high positive personality, high social support and low stressor and low negative coping scores. Negative outcomes were predicted by high stressor, coping and conscientiousness scores, and low positive personality and low social support scores. Cognitive problems were predicted by high stressor and negative coping scores and low positive personality scores.
Time frame: The parameters were measured for 3 continuous days following the baseline visit (day 1, day 2 and day 3) and for 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.
To assess the influence of PEA supplementation on parameters of inflammation.
Interferon-gamma (pg/mL), Interleukin-1 beta (pg/mL), Interleukin 6 (pg/mL), Interleukin 10 (pg/mL), Tumour necrosis factor alpha (pg/mL) levels were measured.
Time frame: The parameters were measured at the baseline visit (day 1) and at the endpoint visit (day 42) of the 6-week supplementation period.
To assess the influence of PEA supplementation on Salivary Cortisol
Salivary Cortisol levels were measured during morning, afternoon and evening for 3 days following each baseline and endpoint visit at home.
Time frame: The parameters were measured in morning and afternoon samples collected over 3 continuous days following the baseline visit (day 1, day 2 and day 3) and 3 continuous days following the endpoint visit (day 42, day 43 and day 44) of the study period.
Ran from Sep 2022 to primary completion in Dec 2023, 15 months.
Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's 15 months is below that.
Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palmidrol
University of Westminster